Home > Blog > Full service phase ii cancer trial

1 min read

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Success Stories Oncology Biologics Full-Service

Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.

A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. 

In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including: 
  • Slow recruitment
  • Data cleansing post-MSU
  • Multi-site location, process, and staffing
DOWNLOAD

 

Meet Veristat. Learn More.


 

1 min read

Meet Veristat at BIO-Europe Spring: March 23-25, 2026 - Lisbon, Portugal

Mar 23, 2026  Veristat Events

🔬 Connecting with the Global Biopharma Community

Veristat is pleased to attend BIO-Europe Spring, where biotech...

1 min read

Meet Veristat at PHUSE US Connect: Advancing Data-Driven Clinical Development

Mar 18, 2026  Veristat Events

🔬 Connecting with the Global Clinical Data and Biostatistics Community

Veristat is pleased to attend PHUSE US Connect...